Harmony Biosciences reports 20% Q1 revenue growth; reaffirms 2025 guidance $820-860M

Harmony Biosciences Holdings, Inc.

2025-Q1 EPS reported $0.78 revenue$184,733,000

Q1 net revenue $184.7M, +20% YoY; GAAP net income $45.6M ($0.78 diluted EPS).
Non-GAAP adjusted net income $60.4M ($1.03 diluted EPS) vs $50.7M ($0.88) YoY.
Reaffirms FY2025 revenue guidance $820-$860M; cash and investments >$600M.
ZYN002 Phase 3 in Fragile X completed recruitment; topline data on track for Q3 2025.
Pitolisant HD Phase 3 registrational trials in narcolepsy & IH on track to initiate Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.